Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 03 November 2025
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors 03 November 2025
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy 02 November 2025
